Vericel Corp (VCEL) research
Vericel Corp- Sector
- Biotechnology
- Last price
- $40.02
- As of
Vericel Corp (VCEL): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-07-30.
As of . Source: SEC EDGAR filings for VCEL. Method and limitations.
Share the VCEL intelligence card
See VCEL live in the terminal
Track VCEL's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live VCEL terminal, freeActive signals for VCEL
- highCONSENSUS_BUY
3 tracked funds increased VCEL this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased VCEL this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +170% to VCEL (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +52% to VCEL (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +184% to VCEL (2026Q2)
FREE, NO ACCOUNT
Every signal on VCEL, as it fires
You are seeing 5 of 29 signals recorded on VCEL since 2026-05-26.
The five above landed across 2 days. The other 24 were recorded on 4 other days. 20 of the 29 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VCEL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 92346J108 · 2026Q2 | $25.8M | 0.02% | , |
| D. E. Shaw & Co., Inc.CUSIP 92346J108 · 2026Q2 | $20.1M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 92346J108 · 2026Q2 | $19.7M | 0.02% | , |
| CITADEL ADVISORS LLCCUSIP 92346J108 · 2026Q2 | $393K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VCEL
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
VCEL against its peers
VCEL's operating margin of 4.0% ranks in the 70th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | VCEL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 276M USD | 108M USD | 70 | 14 |
| Gross margin | 74.4% | n/a | n/a | 2 |
| Operating margin | 4.0% | -100.5% | 70 | 14 |
| Net margin | 6.0% | -76.6% | 72 | 15 |
| Return on equity | 4.7% | -30.2% | 83 | 19 |
| P / E | 125.1x | n/a | n/a | 3 |
Peers (22): KOD, CMPS, URGN, RAPP, ADMA, AGIO, ZBIO, MESO, VIR, PVLA, SRPT, GHRS, BCRX, AUPH, SLS, XNCR, ZYME, ABSI, STOK, BHVN, SEPN, LKFT. Left out: GENB (no annual filing), BRVE (no annual filing), COAG (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (VCEL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more VCEL signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to VCELand get the insider, 13F, options, and confluence read in one view.